Bayer's High-Stakes Week: A Supreme Court Showdown and a Clinical Breakthrough
21.04.2026 - 10:12:35 | boerse-global.de
Bayer shares, which closed at 41.36 EUR on Monday, are navigating a critical confluence of events. The company faces a pivotal legal hearing in Washington D.C. just days after its Annual General Meeting, while its pharmaceutical pipeline delivers promising clinical news. This intense week could define the German conglomerate's trajectory for years to come.
The most significant moment arrives on April 27, when Bayer appears before the US Supreme Court. The justices will hear arguments on whether federal law preempts state-level failure-to-warn lawsuits concerning the herbicide glyphosate. A favorable ruling for Bayer would effectively nullify tens of thousands of such claims. The company has received unexpected support from the Trump Administration, which has backed its legal position, reversing the stance of the previous government. To date, the legacy of the Monsanto acquisition has cost the company over $11 billion in settlements and judgments, with a further 11.8 billion EUR provisioned for ongoing litigation. A final Supreme Court decision is expected by June 2026.
Simultaneously, the company is advancing a nationwide class settlement in Missouri, with a critical deadline for plaintiff opt-outs on June 4. Management anticipates cash outflows for glyphosate settlements alone to reach approximately five billion EUR this year, putting significant pressure on free cash flow.
Should investors sell immediately? Or is it worth buying Bayer?
Away from the courtroom, Bayer's pharmaceutical division is generating robust operational signals. The full data from the OCEANIC-STROKE study, published in the New England Journal of Medicine, showed the drug asundexian reduced the risk of ischemic stroke by 26% compared to a placebo, without an increase in major bleeding. The rate of fatal or disabling strokes fell by nearly one-third. This marks the first time a Factor XIa inhibitor has demonstrated superiority in a Phase III trial for this indication, and the US FDA has already granted it Fast-Track status for stroke prevention.
Furthermore, the kidney and heart drug Kerendia recently posted currency-adjusted growth of 88%, with Bayer targeting peak sales exceeding three billion EUR for the product long-term.
Preceding the Supreme Court hearing, Bayer's virtual Annual General Meeting is set for April 24. Shareholders will vote on a minimal dividend of 0.11 EUR per share and oversee a reshuffle of the Supervisory Board, where Marcel Smits and Alfred Stern will replace Paul Achleitner and Colleen Goggins. Despite the legal overhang, management reaffirms its full-year targets, aiming for group sales above 45 billion EUR and an adjusted operating profit of around 10 billion EUR. Potential US import tariffs on medicines are not currently a concern, as existing trade agreements cap any increases at 15%.
The news flow remains dense in the coming weeks. Bayer will report quarterly figures on May 12, which are likely to include initial assessments of the Supreme Court hearing. If the company can successfully navigate these legal hurdles, its stock—which still shows a substantial year-to-date gain of 91% but currently signals an oversold condition with an RSI of 23.3—may build upon its recent performance.
Ad
Bayer Stock: New Analysis - 21 April
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Bayers Aktien ein!
Für. Immer. Kostenlos.
